CHRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CHRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Coherus BioSciences's Average Total Inventories for the three months ended in Dec. 2024 was $58.9 Mil. Coherus BioSciences's Cost of Goods Sold for the three months ended in Dec. 2024 was $33.9 Mil. Hence, Coherus BioSciences's Days Inventory for the three months ended in Dec. 2024 was 158.65.
The historical rank and industry rank for Coherus BioSciences's Days Inventory or its related term are showing as below:
During the past 13 years, Coherus BioSciences's highest Days Inventory was 261.83. The lowest was 116.39. And the median was 202.53.
Coherus BioSciences's Days Inventory increased from Dec. 2023 (69.81) to Dec. 2024 (158.65). It might indicate that Coherus BioSciences's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year. Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2024 was 0.58.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Coherus BioSciences's Inventory-to-Revenue for the three months ended in Dec. 2024 was 1.09.
The historical data trend for Coherus BioSciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus BioSciences Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
261.83 | 259.45 | 199.04 | 116.39 | 206.01 |
Coherus BioSciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
69.81 | 164.35 | 199.66 | 241.54 | 158.65 |
For the Biotechnology subindustry, Coherus BioSciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Coherus BioSciences's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as
Days Inventory (A: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2023 ) | + | Total Inventories (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (62.605 | + | 70.094) | / | 2 ) | / | 117.553 | * | 365 |
= | 66.3495 | / | 117.553 | * | 365 | ||||
= | 206.01 |
Coherus BioSciences's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (47.64 | + | 70.094) | / | 2 ) | / | 33.858 | * | 365 / 4 |
= | 58.867 | / | 33.858 | * | 365 / 4 | ||||
= | 158.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus BioSciences (NAS:CHRS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 33.858 | / | 58.867 | |
= | 0.58 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coherus BioSciences's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 58.867 | / | 54.144 | |
= | 1.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Coherus BioSciences's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Dennis M Lanfear | director, officer: President and CEO | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Michael Lee Ryan | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Mcdavid Stilwell | officer: Chief Financial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Bryan J Mcmichael | officer: See Remarks | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065 |
Paul Reider | officer: Chief Commercial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jill O'donnell-tormey | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Charles W. Newton | director | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Lee Nisley Newcomer | director | 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Vladimir Vexler | officer: Chief Scientific Officer | 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Vincent R Anicetti | officer: Chief, Quality & Compliance | COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jean-frederic Viret | officer: Chief Financial Officer | ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
Mark Stolper | director | 150 COTNER AVENUE, LOS ANGELES CA 90025 |
Alan C Mendelson | director | ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025 |
Kimberly Jo Tzoumakas | director | 1170 FAIRFAX STREET, BIRMINGHAM MI 48009 |
From GuruFocus
By GuruFocus News • 10-09-2024
By Marketwired • 05-30-2024
By Marketwired • 06-05-2024
By GuruFocus News • 03-11-2025
By GuruFocus News • 11-07-2024
By Marketwired • 03-10-2025
By GuruFocus News • 02-14-2025
By Marketwired • 11-27-2024
By GuruFocus Research • 03-13-2024
By Marketwired • 01-08-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.